🏛️ Verified NIH Record • Updated 2025-04-09
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (NCT03600441)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Xynomic Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
Who can join: Review the eligibility criteria below.
Location: Advocate Medical Group - Park Ridge, Luther Lane - Oncology — Park Ridge, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Advocate Medical Group - Park Ridge, Luther Lane - Oncology — Park Ridge, Illinois
- Norton Cancer Institute - St. Matthews Campus — Louisville, Kentucky
- Clinical Research Alliance Inc — Lake Success, New York
- Manhattan Hematology Oncology Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Bone Marrow Transplant Hematology Oncology Associates — Pittsburgh, Pennsylvania
- Arlington Cancer Center — Arlington, Texas
- Central Texas Veterans Health Care System - NAVREF — Temple, Texas
- Vista Oncology Inc. PS — Olympia, Washington
- Centre Hospitalier de Perpignan — Perpignan, Pyrénées-Orientales
- Hospital Universitario de Donostia — Donostia / San Sebastian, Guipúzcoa
- Hospital Universitario Vall d'Hebrón — Barcelona,
- Hospital del Mar — Barcelona,
- C.H. Regional Reina Sofia — Córdoba,
- Hospital Universitario Infanta Leonor — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Follicular Lymphoma
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
- Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
- Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
- Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Concord, California
Explore by condition: All Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.